Liminal BioSciences Inc. (LMNL)の価格はいくらですか

Liminal BioSciences Inc. (LMNL)の価格は$8.50です

Liminal BioSciences Inc. (LMNL)の時価総額は何ですか

Liminal BioSciences Inc. (LMNL)の時価総額は$719.10Kです

Liminal BioSciences Inc. (LMNL) の利益

Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammatory, fibrotic, and metabolic diseases, with its operations spanning Canada and the United Kingdom. Its flagship drug candidate, fezagepras (identified as PBI-4050), has successfully advanced through Phase I clinical trials. This agent, along with its related derivatives, is undergoing investigation for potential application in treating idiopathic fibrosis affecting the lungs, liver, heart, or skin, as well as various respiratory conditions. Furthermore, Liminal is advancing antagonist programs, including G-protein coupled receptor 84 (GPR84) and Oxo-eicosanoid receptor 1 (OXER1), both of which are currently in preclinical development. Formerly known as Prometic Life Sciences Inc., the company adopted the name Liminal BioSciences Inc. in October 2019. Established in 1994, its corporate headquarters are located in Laval, Canada.

年	利益	変化
提供された日付のデータは十分ではありません。

年

利益

変化

提供された日付のデータは十分ではありません。

企業	利益	利益の差	国
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$3.01B	-	BE

企業

利益

利益の差

国